FDA panel reviews telmisartan
Links shared publicly online about this topic.
- 1,861total visits
FDA panel reviews telmisartan
View full resource at theheart.org
Tags: Post Heart Attack Medication, Heart Failure Medication, High Blood Pressure Medication, FDA, Micardis, Delix, Tritace, Altace
Most Recently Shared on July 29, 2009 at 9:39 pm By:
heartwire: No to expanded indication for telmisartan, except in ramipril-intolerant patients, says FDA.. http://bit.ly/HGHJa
Weight loss pill Qnexa wins panel vote and awaits approval
news-medical.net — “The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.” View full resource at news-medical.net
Most Recently Shared on April 5, 2012 at 11:08 pm By:
Diet News: Weight loss pill Qnexa wins panel vote and awaits approval: The drug was rejected in a 10-6 vote the ... http://t.co/rGbONdEq
A.M. Vitals: Roberts Leaves Wiggle Room on Health-Law Case - Health Blog - WSJ
blogs.wsj.com — “Also: An FDA advisory panel recommends more testing to make sure obesity drugs don't cause heart attacks, and another FDA panel will review data on metal-on-metal him implants in June.” View full resource at blogs.wsj.com
Most Recently Shared on March 30, 2012 at 7:08 pm By:
Jason Bellak, MD Doctor, Internist, Physician, and Active Health Library
A.M. Vitals: Roberts Leaves Wiggle Room on Health-Law Case via @wsj http://t.co/CHIdeuFu
UPDATE 2-FDA seeks more advice on metal hip implants | Reuters
reuters.com — “* FDA responds to concerns about all-metal hip implants* Advisory panel review set for June 27-28* Review could lead to more rigorous standardsMarch 29 (Reuters) - The U.S. Food and Drug Administrationresponded” View full resource at reuters.com
Most Recently Shared on March 29, 2012 at 8:00 pm By:
Cary Byrd - eDrugSearch.com Pharma and Health Advocate
UPDATE 2-FDA seeks more advice on metal hip implants | Reuters http://t.co/4QjFaNXz
FDA Panel Urges Review of Stryker Stent - WSJ.com
online.wsj.com — “A federal advisory panel said there was insufficient evidence to support keeping Stryker's Wingspan stent on the market, raising the possibility that the Food and Drug Administration might withdraw its approval of the stroke-treatment product.” View full resource at online.wsj.com
Most Recently Shared on March 26, 2012 at 12:39 am By:
FDA Panel Urges Review of Stryker Stent http://t.co/vZKg2nDs
Medical News:FDA Panel Review May Ground Wingspan Stent - in Cardiovascular, Prevention from MedPage Today
medpagetoday.com — “Medical News:FDA Panel Review May Ground Wingspan Stent - in Cardiovascular, Prevention from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 24, 2012 at 3:49 am By:
FDA Panel Review May Ground Wingspan Stent: WASHINGTON (MedPage Today) -- An FDA advisory… http://t.co/6tXijhDV
FDA Panel Review May Ground Wingspan Stent - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- An FDA advisory committee has indicated that there is insufficient evidence to say that the Wingspan intracranial stent has a long-term benefit that outweighs the device's risks.” View full resource at qualitypointtech.net
Most Recently Shared on March 24, 2012 at 3:45 am By:
FDA Panel Review May Ground Wingspan Stent: WASHINGTON (MedPage Today) -- An FDA advisory committee has indicated ... http://t.co/NhNnwJEn
Medical News:FDA Panel Review May Ground Wingspan Stent - in Cardiovascular, Prevention from MedPage Today
medpagetoday.com — “Medical News:FDA Panel Review May Ground Wingspan Stent - in Cardiovascular, Prevention from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 24, 2012 at 3:12 am By:
FDA Panel Review May Ground Wingspan Stent http://t.co/ibNOPYN2
Panel to Review Merck, Glaxo Cancer Drugs - WSJ.com
online.wsj.com — “An FDA panel on Tuesday will review new cancer drugs by Merck and Glaxo.” View full resource at online.wsj.com
Most Recently Shared on March 16, 2012 at 4:27 pm By:
Panel to Review Merck, Glaxo Drugs http://t.co/n84AAwUn
UCLA Professor Says Qnexa Has The "Highest Efficacy" for Weight Loss
emaxhealth.com — “After a second review of its effectiveness and safety profile, Qnexa, an anti-obesity drug by Vivus Inc, has gained an FDA panel's approval and may so...” View full resource at emaxhealth.com
Most Recently Shared on February 23, 2012 at 5:05 pm By:
Denise Reynolds RD Nutritionist and Dietitian
UCLA Professor on FDA Panel Says Qnexa Has The "Highest Efficacy" for Weight Loss http://t.co/tCgqYnQr
UPDATE 2-US FDA staff focus on safety of Forest lung drug | Reuters
reuters.com — “* Drug worked to treat chronic lung disease-FDA staff* Uncertain signals about heart safety with drug* FDA advisory panel to review drug on ThursdayBy Anna YukhananovWASHINGTON, Feb 21 (Reuters) -” View full resource at reuters.com
Most Recently Shared on February 21, 2012 at 2:24 pm By:
RT @JohnCFierce: FDA regulators like Forest COPD drug's efficacy, but raise questions on cardio risks for the class. http://t.co/qxyBK25k
FDA notes concerns about Vivus diet pill safety ahead of panel - FierceBiotech
fiercebiotech.com — “U.S. regulators have cited concerns about the safety of Vivus’ ($VVUS) experimental diet pill Qnexa in review documents as the California drug developer pursues the first FDA approval of a Read more...” View full resource at fiercebiotech.com
Most Recently Shared on February 17, 2012 at 3:52 pm By:
FDA notes concerns about Vivus diet pill safety ahead of panel http://t.co/Z8Nc7jXR $VVUS
UPDATE 1-Pfizer says its drug is best hope for Alzheimer's - Yahoo! Finance UK
uk.finance.yahoo.com — “Read 'UPDATE 1-Pfizer says its drug is best hope for Alzheimer's' on Yahoo! Finance UK. * Says prior trials suggest edge over Lilly Alzheimer's drug * Says Prevnar 13 pneumonia data expected by 2013 * Expects FDA panel to review arthritis drug (Adds quotes from research chief, details on ...” View full resource at uk.finance.yahoo.com
Most Recently Shared on February 14, 2012 at 7:37 pm By:
UPDATE 1-Pfizer says its drug is best hope for Alzheimer's: * Says prior trials suggest edge over Lilly Alzheime... http://t.co/I53zjiUn
Oops, She Did It Again! FDA Disinvites Another Advisor - Yahoo! News
news.yahoo.com — “From Yahoo! News: Today an FDA advisory panel will meet to review the safety of oral contraceptives that contain drospirenone. One person who will not be voting on the panel is Sidney Wolfe, the well known consumer advocate and pharma critic. Wolfe was originally listed as a panel member, but then, only 2 days before the [...]” View full resource at news.yahoo.com
Most Recently Shared on December 10, 2011 at 8:11 am By:
Maggie Mahar Doctor and PhD
Oops, She Did It Again! FDA Disinvites Another Advisor - Yahoo! News http://t.co/bCXrBgJs via @YahooNews
Oops, She Did It Again! FDA Disinvites Another Advisor - Forbes
forbes.com — “Today an FDA advisory panel will meet to review the safety of oral contraceptives that contain drospirenone. One person who will not be voting on the panel is Sidney Wolfe, the well known consumer advocate and pharma critic. Wolfe was originally listed as a panel member, but then, only 2 days before the [...]” View full resource at forbes.com
Most Recently Shared on December 8, 2011 at 3:21 pm By:
Scott Strumello Patient Expert
Oops, She Did It Again! FDA Disinvites Another Advisor - Forbes http://t.co/PbW7RsNq
FDA Gives Favorable Review to SHARP Ahead of Vytorin Advisory Panel - Forbes
forbes.com — “In preparation for Wednesday's meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, an FDA reviewer has generally endorsed the positive interpretation of the SHARP (Study of Heart and Renal Protection) trial of Vytorin (ezetimibe and simvastatin) in chronic kidney disease (CKD). Based on the results of SHARP Merck is seeking [...]” View full resource at forbes.com
Most Recently Shared on October 30, 2011 at 9:01 pm By:
Drugs and Devices OW OW Health
FDA Gives Favorable Review to SHARP Ahead of Vytorin Advisory Panel: In preparation for Wednesday’s meetin... http://t.co/vYawcGFW #drug
Advertisement
